Table 2.
Results of the network meta-analysis concerning clinical success rate and adverse event rate.
| Clinical Success Rate | Adverse Event Rate | |||
|---|---|---|---|---|
| Risk Ratio (95% CI) | Quality of Evidence | Risk Ratio (95% CI) | Quality of Evidence | |
| All treatments vs. PTBD | ||||
| EUS-CD | 1.01 (0.88–1.17) | Low | 0.53 (0.21–1.32) | Low |
| EUS-HG | 1.03 (0.86–1.22) | Low | 0.45 (0.15–1.33) | Low |
| Surgery | 1.42 (0.90–2.24) | Low | 0.35 (0.05–2.31) | Low |
| vs. EUS-CD | ||||
| EUS-HG | 1.01 (0.87–1.17) | Low | 0.85 (0.39–1.82) | Low |
| Surgery | 1.40 (0.91–2.13) | Low | 0.66 (0.12–3.46) | Low |
| vs. EUS-HG | ||||
| Surgery | 1.38 (0.88–2.16) | Low | 0.78 (0.12–4.83) | Low |
Abbreviations: EUS-CD, endoscopic ultrasound choledochoduodenostomy; EUS-HG, endoscopic ultrasound hepatico-gastrostomy; PTBD, percutaneous trans-hepatic biliary drainage.